ALMS vs. DNLI
ALMS (Alumis Inc) and DNLI (Denali Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, ALMS returned 584.02% vs 71.28% for DNLI. Their 0.25 correlation means their historical movements had little consistent relationship.
Performance
ALMS vs. DNLI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALMS achieves a 189.45% return, which is significantly higher than DNLI's 39.43% return.
ALMS
- 1D
- -2.42%
- 1M
- 6.60%
- 6M
- 15.26%
- YTD
- 189.45%
- 1Y
- 584.02%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 42.40%
DNLI
- 1D
- -5.46%
- 1M
- -10.88%
- 6M
- 5.89%
- YTD
- 39.43%
- 1Y
- 71.28%
- 3Y*
- -6.67%
- 5Y*
- -14.72%
- 10Y*
- —
- ALL TIME*
- 0.77%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
ALMS Alumis Inc | $25.75M | $38.17M | $32.73M |
| $31.93M | $41.06M | $41.74M |
ALMS vs. DNLI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ALMS Alumis Inc | 189.45% | 24.17% | -41.78% |
DNLI Denali Therapeutics Inc. | 39.43% | -18.99% | -11.28% |
Correlation
The correlation between ALMS and DNLI is 0.33, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.33 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2024 | 0.25 |
Fundamentals
ALMS:
$3.49B
DNLI:
$3.65B
ALMS:
-$2.13
DNLI:
-$2.85
ALMS:
6.23
DNLI:
4.64
ALMS:
$8.40M
DNLI:
$0.00
ALMS:
$5.79M
DNLI:
-$2.87M
ALMS:
-$411.89M
DNLI:
-$526.60M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALMS vs. DNLI — Risk / Return Rank
ALMS
DNLI
ALMS vs. DNLI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Alumis Inc (ALMS) and Denali Therapeutics Inc. (DNLI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALMS | DNLI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.71 | ||
| Sortino ratioReturn per unit of downside risk | +4.08 | ||
| Omega ratioGain probability vs. loss probability | 1.73 | 1.22 | +0.50 |
| Calmar ratioReturn relative to maximum drawdown | 16.03 | 3.26 | +12.77 |
| Martin ratioReturn relative to average drawdown | 41.16 | 6.35 | +34.81 |
Loading charts...
Drawdowns
ALMS vs. DNLI - Drawdown Comparison
The maximum ALMS drawdown since its inception was -79.26%, smaller than the maximum DNLI drawdown of -87.74%. Use the drawdown chart below to compare losses from any high point for ALMS and DNLI.
Loading charts...
Drawdown Indicators
| ALMS | DNLI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.26% | -87.74% | +8.48% |
Max Drawdown (1Y)Largest decline over 1 year | -36.66% | -20.49% | -16.17% |
Max Drawdown (3Y)Largest decline over 3 years | — | -63.68% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -79.51% | — |
Current DrawdownCurrent decline from peak | -6.77% | -75.40% | +68.63% |
Average DrawdownAverage peak-to-trough decline | -36.85% | -51.88% | +15.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.25% | 10.50% | +3.75% |
Volatility
ALMS vs. DNLI - Volatility Comparison
Alumis Inc (ALMS) and Denali Therapeutics Inc. (DNLI) have volatilities of 20.35% and 19.65%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALMS | DNLI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.35% | 19.65% | +0.70% |
Volatility (6M)Calculated over the trailing 6-month period | 50.42% | 41.60% | +8.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 121.01% | 58.14% | +62.87% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 114.08% | 62.32% | +51.76% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 114.08% | 65.04% | +49.04% |
Dividends
ALMS vs. DNLI - Dividend Comparison
Neither ALMS nor DNLI has paid dividends to shareholders.
Financials
ALMS vs. DNLI - Financials Comparison
This section allows you to compare key financial metrics between Alumis Inc and Denali Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ALMS and DNLI have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALMS has higher volatility (20.35%) compared to DNLI (19.65%). In terms of maximum drawdown, ALMS dropped -79.26% vs DNLI's -87.74%.
ALMS currently has the higher Sharpe Ratio (4.86 vs 1.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALMS and DNLI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer